NCT00733577View on ClinicalTrials.gov

A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 11, 2008

Primary Completion Date

March 3, 2009

Study Completion Date

March 3, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

SB756050

doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations

Trial Locations (4)

32809

GSK Investigational Site, Orlando

33169

GSK Investigational Site, Miami

78209

GSK Investigational Site, San Antonio

07601

GSK Investigational Site, Hackensack

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY